Nivolumab/relatlimab
Combination drug
From Wikipedia, the free encyclopedia
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma.[10] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.[10] It is given by intravenous infusion.[10]
| Combination of | |
|---|---|
| Nivolumab | Programmed death receptor-1 (PD-1) blocking antibody |
| Relatlimab | Lymphocyte activation gene-3 (LAG-3) blocking antibody |
| Clinical data | |
| Trade names | Opdualag |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622037 |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The combination was approved for medical use in the United States in March 2022,[10][12] and in the European Union in September 2022.[11] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[13][14]
Medical uses
The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.[10][11]
It is also currently being researched as a possible treatment for Parkinson's disease and other neurodegenerative conditions, based on early evidence that it may prevent the spread of pathologically misfolded alpha-synuclein protein (Lewy bodies) through neurons in the substantia nigra region of the brain.[15]
Society and culture
Legal status
In July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Opdualag, intended for the treatment of melanoma.[11][16] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[16] Opdualag was approved for medical use in the European Union in September 2022.[11][17]
In January 2024, the National Institute for Health and Care Excellence (NICE) recommended nivolumab-relatlimab[18] as a first-line treatment of advanced melanoma in patients aged 12 years and older.[19]
